Semaglutide oral - Guangzhou Dazhou Biomedicine
Alternative Names: SHX-021Latest Information Update: 22 Dec 2022
At a glance
- Originator Guangzhou Dazhou Biomedicine
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 22 Dec 2022 QC feedback incoporated
- 21 Nov 2022 Preclinical trials in Obesity in USA (PO) (Guangzhou Dazhou Biomedicine, November 2022)
- 21 Nov 2022 Preclinical trials in Type 2 diabetes mellitus in USA (PO) (Guangzhou Dazhou Biomedicine, November 2022)